Ishiyama Ken
Department of Hematology, Kanazawa University Hospital.
Rinsho Ketsueki. 2016 May;57(5):525-30. doi: 10.11406/rinketsu.57.525.
Acquired aplastic anemia (AA) is a hematopoietic dyscrasia characterized by pancytopenia and bone marrow hypoplasia. AA is considered to be caused mainly by T-cell attacks on hematopoietic stem cells, as assumption based on good responses to T-cell specific immunosuppressive therapy (IST). Several markers, such as HLA-DRB1(*)1501 and an increase in the percentage of paroxysmal nocturnal hemoglobinuria (PNH) phenotype cells, have been shown to represent the immune pathophysiology of AA. However, little is known about the pathogenesis of AA. This review article focuses on immune mechanisms underlying the development of AA and the roles of the aforementioned markers in the management of bone marrow failure.
获得性再生障碍性贫血(AA)是一种以全血细胞减少和骨髓发育不全为特征的造血障碍。AA被认为主要是由T细胞对造血干细胞的攻击引起的,这一假设基于对T细胞特异性免疫抑制治疗(IST)的良好反应。一些标志物,如HLA-DRB1(*)1501和阵发性睡眠性血红蛋白尿(PNH)表型细胞百分比的增加,已被证明代表了AA的免疫病理生理学。然而,关于AA的发病机制知之甚少。这篇综述文章重点关注AA发生发展的免疫机制以及上述标志物在骨髓衰竭管理中的作用。